임상적 지표를 이용한 대뇌 아밀로이드 단백 축적 여부 예측모델 개발
Development of Cerebral Amyloid Positivity Predicting Models Using Clinical Indicators
2
조회
0
다운로드
0
인용
0
참고문헌
초록
ObjectivesZZAmyloid β positron emission tomography (Aβ PET) is widely used as a diagnostic tool in patients who have symptoms of cognitive impairment, however, this diagnostic examination is too expensive. Thus, predicting the positivity of Aβ PET before patients undergo the examination is essential. We aimed to analyze clinical predictors of patients who underwent Aβ PET retrospectively, and to develop a predicting model of Aβ PET positivity. MethodsZZ468 patients who underwent Aβ PET with cognitive impairment were recruited and their clinical indicators were analyzed retrospectively. We specified the primary outcome as Aβ PET positivity, and included variables such as age, sex, body mass index, diastolic blood pressure, systolic blood pressure, education, dementia family history, Mini Mental Status Examination (MMSE), Clinical Dementia Rating (CDR), Clinical Dementia Rating-Sum of Box (CDR-SB), hypertension (HTN), diabetes mellitus (DM) and presence of apolipoprotein E (ApoE) E4 as potential predictors. We developed three final models of amyloid positivity prediction for total subjects, mild cognitive impairment (MCI) and Alzheimer’s disease (AD) dementia using a multivariate stepwise logistic regression analysis. Receiver operating characteristic (ROC) curve analysis was performed and the area under curve (AUC) value was calculated for the ROC curve. ResultsZZAβ PET negative patients were 49.6% (n = 232), and Aβ PET positive patients were 50.4% (n = 236). In the final model of all subjects, older age, female sex, presence of ApoE E4 and lower MMSE are associated with Aβ PET positivity. The AUC value was 0.296. In the final model of MCI subjects (n = 244), older age and presence of ApoE E4 are associated with Aβ PET positivity. The AUC value was 0.725. In the final model of AD subjects (n = 173), lower MMSE scores, the presence of ApoE E4 and history of HTN are associated with Aβ PET positivity. The AUC value was 0.681. ConclusionsZZThe cerebral amyloid positivity model, which was based on commonly available clinical indicators, can be useful for prediction of amyloid PET positivity in MCI or AD patients.
Abstract
ObjectivesZZAmyloid β positron emission tomography (Aβ PET) is widely used as a diagnostic tool in patients who have symptoms of cognitive impairment, however, this diagnostic examination is too expensive. Thus, predicting the positivity of Aβ PET before patients undergo the examination is essential. We aimed to analyze clinical predictors of patients who underwent Aβ PET retrospectively, and to develop a predicting model of Aβ PET positivity. MethodsZZ468 patients who underwent Aβ PET with cognitive impairment were recruited and their clinical indicators were analyzed retrospectively. We specified the primary outcome as Aβ PET positivity, and included variables such as age, sex, body mass index, diastolic blood pressure, systolic blood pressure, education, dementia family history, Mini Mental Status Examination (MMSE), Clinical Dementia Rating (CDR), Clinical Dementia Rating-Sum of Box (CDR-SB), hypertension (HTN), diabetes mellitus (DM) and presence of apolipoprotein E (ApoE) E4 as potential predictors. We developed three final models of amyloid positivity prediction for total subjects, mild cognitive impairment (MCI) and Alzheimer’s disease (AD) dementia using a multivariate stepwise logistic regression analysis. Receiver operating characteristic (ROC) curve analysis was performed and the area under curve (AUC) value was calculated for the ROC curve. ResultsZZAβ PET negative patients were 49.6% (n = 232), and Aβ PET positive patients were 50.4% (n = 236). In the final model of all subjects, older age, female sex, presence of ApoE E4 and lower MMSE are associated with Aβ PET positivity. The AUC value was 0.296. In the final model of MCI subjects (n = 244), older age and presence of ApoE E4 are associated with Aβ PET positivity. The AUC value was 0.725. In the final model of AD subjects (n = 173), lower MMSE scores, the presence of ApoE E4 and history of HTN are associated with Aβ PET positivity. The AUC value was 0.681. ConclusionsZZThe cerebral amyloid positivity model, which was based on commonly available clinical indicators, can be useful for prediction of amyloid PET positivity in MCI or AD patients.
참고문헌 (32)
- Alzheimer"s Association, "2013 Alzheimer’s disease facts and figures", Alzheimers Dement, 9, pp.208~245 (2013)
- Korean Dementia Observatory 2019, "Lee JS", National Institute of Dementia, ~ (2020)
- Bateman RJ, "Clinical and biomarker changes in dominantly inherited Alzheimer"s disease", N Engl J Med, 367, pp.795~804 (2012)
- Beach TG, "Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010", J Neuropathol Exp Neurol, 71, pp.266~273 (2012)
- Ossenkoppele R, "Impact of molecular imaging on the diagnostic process in a memory clinic", Alzheimers Dement, 9, pp.414~421 (2013)
- Ossenkoppele R, "Prevalence of amyloid PET positivity in dementia syndromes : a meta-analysis", JAMA, 313, pp.1939~1949 (2015)
- 전소연, "알츠하이머병 치매에서 대뇌 아밀로이드 축적 여부에 따른 임상적 특성의 차이", 노인정신의학, 20(2), pp.68~74 (2016), 대한노인정신의학회
- Risacher SL, "The role of apolipoprotein E(APOE)genotype in early mild cognitive impairment(E-MCI)", Front Aging Neurosci, 5, pp.11~ (2013)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5", pp.585~589 (2013), American Psychaitric Association
- McKhann GM, "The diagnosis of dementia due to Alzheimer"s disease : recommendations from the National Institute on Aging-Alzheimer"s Association workgroups on diagnostic guidelines for Alzheimer"s disease", Alzheimers Dement, 7, pp.263~269 (2011)
- 강동우, "알츠하이머병 환자의 뇌 영상 검사의 최신 지견과임상 적용 방법", 신경정신의학, 57(1), pp.12~22 (2018), 대한신경정신의학회[DOI]
- Barthel H, "Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study", Lancet Neurol, 10, pp.424~435 (2011)
- Kim HJ, "18FAV-1451 PET imaging in three patients with probable cerebral amyloid angiopathy", J Alzheimers Dis, 57, pp.711~716 (2017)
- flutemetamol brain images from end-of-life and amnestic MCI subjects, "J Nucl Med", 2017, 1250~
- Martínez G, "18F PET with florbetapir for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)", Cochrane Database Syst Rev, 11 (2017)
- Kang Y, "A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
- Choi SH, "Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale", J Korean Neurol Assoc, 19, pp.585~591 (2001)
- Haghighi M, "Identifying cost-effective predictive rules of amyloid-β level by integrating neuropsychological tests and plasma-based markers", J Alzheimers Dis, 43, pp.1261~1270 (2015)
- Kim SE, "A nomogram for predicting amyloid PET positivity in amnestic mild cognitive impairment", J Alzheimers Dis, 66, pp.681~691 (2018)
- Lee JH, "Prediction of cerebral amyloid with common information obtained from memory clinic practice", Front Aging Neurosci, 10, pp.309~ (2018)
- Mielke MM, "Indicators of amyloid burden in a population-based study of cognitively normal elderly", Neurology, 79, pp.1570~1577 (2012)
- Chételat G, "Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease", Neuroimage Clin, 2, pp.356~365 (2013)
- Bischof GN, "Amyloid deposition in younger adults is linked to episodic memory performance", Neurology, 87, pp.2562~2566 (2016)
- Landau SM, "Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI", Neurology, 86, pp.1377~1385 (2016)
- Tomadesso C, "Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients", Alzheimers Dement(Amst), 10, pp.269~277 (2018)
- Wolk DA, "Amyloid imaging in mild cognitive impairment subtypes", Ann Neurol, 65, pp.557~568 (2009)
- Schneider JA, "High blood pressure and microinfarcts: a link between vascular risk factors, dementia, and clinical Alzheimer’s disease", J Am Geriatr Soc, 57, pp.2146~2147 (2009)
- Wiseman RM, "Hippocampal atrophy, whole brain volume, and white matter lesions in older hypertensive subjects", Neurology, 63, pp.1892~1897 (2004)
- Glodzik L, "Alzheimer"s disease markers, hypertension, and gray matter damage in normal elderly", Neurobiol Aging, 33, pp.1215~1227 (2012)
- Beauchet O, "Blood pressure levels and brain volume reduction : a systematic review and meta-analysis", J Hypertens, 31, pp.1502~1516 (2013)
- Power MC, "Life-course blood pressure in relation to brain volumes", Alzheimers Dement, 12, pp.890~899 (2016)
- Vemuri P, "Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals", JAMA Neurol, 74, pp.718~726 (2017)